Free Cancer Report

Book Appointment with Dr Sandip Shah in Ahmedabad

Dr Sandip Shah

Hemato Oncologist

25 Years Exp. Ahmedabad

Hematological Cancer

Sterling Hospitals, Ahmedabad

25 years of experience

MBBS, MD, DM

Ahmedabad

About Dr Sandip Shah:

Another leading name in Oncology, Dr Shah began his practice in 1986. He is a consultant medical oncologist and hematologist and is also affiliated to the Gujarat Cancer & Research Institute (GCRI), Ahmedabad as an associate professor of medical Oncology and in-charge of bone marrow transplantation unit. He is also attached to the Rajasthan Hospital, Jivraj Hospital and is on the panel of ONGC. He is an ex-president of the Association of Physicians of Ahmedabad. He has trained in hematology and medical Oncology from reputed institutions such as GCRI, Tata Memorial Hospital & KEM Hospital Mumbai. He has also taken training in bone marrow transplantation at GCRI

Education:

MBBS, MD, DM

Experience:

Dr. Sandip Shah is consultant at Hemato Oncology Clinic, HCG Medisurge Hospital and Rajasthan Hospitals, Ahmedabad

Memberships:

Association of Physician of Gujarat

Areas of interest:

Blood Cancer, Blood Cancer.

Research publications:

Viswabandya, Auro & Mukhopadhyay, Asis & Shah, Sandip & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2016). Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (MabtheraŠ) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma. Blood. 128. 5391-5391. https://doi.org/10.1182/blood.V128.22.5391.5391 Shah, Sandip & Viswabandya, Auro & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2017). Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 35. 7550-7550. https://doi.org/10.1200/JCO.2017.35.15_suppl.7550 Viswabandya, Auro & Shah, Sandip & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2019). Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. Journal of Global Oncology. 5. 1-13. https://doi.org/10.1200/JGO.19.00248

Specialisation

Blood Cancer, Blood Cancer.